Trial · NCT02408549
Results by group595
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 595
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period | All Participants (Lacosamide) | 222 | Participants | ||
| Number of Study Participants Withdrawn Due to TEAEs | All Participants (Lacosamide) | 19 | Participants | ||
| Number of Study Participants With New Appearance of Absence and/or Myoclonic Seizures During the Treatment Period | All Participants (Lacosamide) | Absence seizures | 3 | Participants | |
| Number of Study Participants With New Appearance of Absence and/or Myoclonic Seizures During the Treatment Period | All Participants (Lacosamide) | Myoclonic seizures | 5 | Participants | |
| Number of Study Participants With an Increase of up to 25% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | All Participants (Lacosamide) | 5 | Participants | ||
Number of Study Participants With an Increase of Greater Than (>)25% to 50% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | All Participants (Lacosamide) | 1 | Participants | ||
| Number of Study Participants With an Increase of >50% to 75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | All Participants (Lacosamide) | 0 | Participants | ||
| Number of Study Participants With an Increase of >75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | All Participants (Lacosamide) | 0 | Participants | ||
| Number of Study Participants With an Increase of up to 25% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | All Participants (Lacosamide) | 4 | Participants | ||
| Number of Study Participants With an Increase of >25% to 50% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | All Participants (Lacosamide) | 1 | Participants | ||
| Number of Study Participants With an Increase of >50% to 75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | All Participants (Lacosamide) | 1 | Participants | ||
| Number of Study Participants With an Increase of >75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) | All Participants (Lacosamide) | 2 | Participants | ||
| Percentage of Study Participants With at Least 50% Worsening in Days With Absence Seizures | All Participants (Lacosamide) | 0 | percentage of participants | ||
| Percentage of Study Participants With at Least 50% Worsening in Days With Myoclonic Seizures | All Participants (Lacosamide) | 3.2 | percentage of participants | ||
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hemoglobin) | All Participants (Lacosamide) | Low: Week (Wk) 78 (2-<17 y) | 14.3 | percentage of participants | |
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hemoglobin) | All Participants (Lacosamide) | Low: Wk 0 (>=17 y) | 3.7 | percentage of participants | |
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hemoglobin) | All Participants (Lacosamide) | Low: Wk 2 (>=17 y) | 0.5 | percentage of participants | |
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hemoglobin) | All Participants (Lacosamide) | Low: Wk 118 (>=17 y) | 0.8 | percentage of participants | |
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hemoglobin) | All Participants (Lacosamide) | Low: Wk 166 (>=17 y) | 1.2 | percentage of participants | |
| Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hemoglobin) | All Participants (Lacosamide) | Low: Wk 214 (>=17 y) | 2.5 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02408549/results